# LCL521 dihydrochloride

Cat. No.: HY-103593A CAS No.: 1226759-47-2 Molecular Formula:  $C_{31}H_{54}Cl_2N_4O_7$ Molecular Weight: 665.69

Target: Phospholipase

Pathway: Metabolic Enzyme/Protease

Storage: -20°C, sealed storage, away from moisture

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

**Product** Data Sheet

#### **SOLVENT & SOLUBILITY**

H<sub>2</sub>O: 100 mg/mL (150.22 mM; Need ultrasonic) In Vitro

DMSO: 20.83 mg/mL (31.29 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.5022 mL	7.5110 mL	15.0220 mL
	5 mM	0.3004 mL	1.5022 mL	3.0044 mL
	10 mM	0.1502 mL	0.7511 mL	1.5022 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: PBS Solubility: 50 mg/mL (75.11 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.12 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (3.12 mM); Clear solution
- 4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.12 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	LCL521 dihydrochloride is an acid ceramidase (ACDase) inhibitor. LCL521 also inhibits the lysosomal acid sphingomyelinase (ASMase) <sup>[1]</sup> .
IC <sub>50</sub> & Target	ACDase, ASMase <sup>[1]</sup>
In Vitro	LCL521 (1 μM) acts as a potent inhibitor of cellular ACDase activity, whereas 10 μM LCL521 has an additional, decreased

affect on the  $\alpha$ -form of this enzyme. LCL521 (10 $\mu$ M) causes a time-dependent (1 hours and 5 hours) decrease of the  $\alpha$ -ACDase form in MCF7 cells<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **CUSTOMER VALIDATION**

• Nat Immunol. 2023 May;24(5):802-813.

See more customer validations on  $\underline{www.MedChemExpress.com}$ 

#### **REFERENCES**

[1]. Bai A, et al. Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs. Bioorg Med Chem. 2014 Dec 15;22(24):6933-44.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com